| 000 | 01801 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250518023554.0 | ||
| 264 | 0 | _c20190531 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1873-0183 | ||
| 024 | 7 |
_a10.1016/j.autrev.2018.11.004 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aUgolini-Lopes, Michelle Remião | |
| 245 | 0 | 0 |
_aEnhanced type I interferon gene signature in primary antiphospholipid syndrome: Association with earlier disease onset and preeclampsia. _h[electronic resource] |
| 260 |
_bAutoimmunity reviews _cApr 2019 |
||
| 300 |
_a393-398 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAge of Onset |
| 650 | 0 | 4 |
_aAntiphospholipid Syndrome _xcomplications |
| 650 | 0 | 4 |
_aAutoantibodies _ximmunology |
| 650 | 0 | 4 | _aCase-Control Studies |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aGene Expression _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aInterferon Type I _xpharmacology |
| 650 | 0 | 4 |
_aLeukocytes, Mononuclear _xdrug effects |
| 650 | 0 | 4 |
_aLupus Erythematosus, Systemic _ximmunology |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPre-Eclampsia _xepidemiology |
| 650 | 0 | 4 | _aPregnancy |
| 650 | 0 | 4 | _aPrevalence |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 |
_aTranscriptome _xdrug effects |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aTorrezan, Giovana Tardin | |
| 700 | 1 | _aGândara, Ana Paula Rossi | |
| 700 | 1 | _aOlivieri, Eloisa Helena Ribeiro | |
| 700 | 1 | _aNascimento, Iana Souza | |
| 700 | 1 | _aOkazaki, Erica | |
| 700 | 1 | _aBonfá, Eloisa | |
| 700 | 1 | _aCarraro, Dirce Maria | |
| 700 | 1 | _ade Andrade, Danieli Castro Oliveira | |
| 773 | 0 |
_tAutoimmunity reviews _gvol. 18 _gno. 4 _gp. 393-398 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.autrev.2018.11.004 _zAvailable from publisher's website |
| 999 |
_c29380823 _d29380823 |
||